



EFFECTIVE DATE: 01|01|2014

POLICY LAST UPDATED: 10|6|2015

OVERVIEW

The policy reflects the policy for Gender Reassignment Surgery (GRS) applicable to BlueCHiP for Medicare and limited Commercial products that have included coverage for gender reassignment treatment.

MEDICAL CRITERIA

None

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for those limited Commercial groups that have included coverage for this service.

POLICY STATEMENT

BlueCHiP for Medicare and Limited Commercial Products

Preauthorization is recommended to determine if the member is eligible for coverage and to assist in maximizing the benefit.

When a benefit for gender reassignment surgery exists, it is considered a covered service when documentation submitted confirms that all of the following criteria are met:

- The individual is at least 18 years of age
- The individual has been diagnosed with the gender identity disorder (GID) or gender dysphoria of transsexualism
- The individual has successfully lived and worked within the desired gender role full-time for at least 12 months (real-life experience) without returning to the original gender

Surgical Treatment for Gender Reassignment

When a covered benefit for gender reassignment surgery exists and all of the above criteria are met, the following surgeries are medically necessary for transwomen (male to female):

- Orchiectomy (54520, 54690)
- Penectomy (54125)
- Vaginoplasty (57335)
- Colovaginoplasty (57291-57292)
- Clitoroplasty (56805)
- Labiaplasty (58999)
- Breast Augmentation (19324-19325) Note: augmentation mammoplasty (including breast prosthesis if necessary) if the physician prescribing hormones and the surgeon have documented that breast enlargement after undergoing hormone treatment for 12 months is not sufficient for comfort in the social role
- Trachea shave/reduction thyroid chondroplasty: reduction of the thyroid cartilage (31899)

When a covered benefit for gender reassignment surgery exists and all of the above criteria are met, the following surgeries are medically necessary for transmen (female to male):

- Breast reconstruction (e.g., mastectomy (19303-19304), reduction mammoplasty (19318])

- Hysterectomy (58150, 58262, 58291, 58552, 58554, 58571, 58573)
- Salpingo-oophorectomy (58661)
- Colpectomy/Vaginectomy (57110)
- Metoidioplasty (55899)
- Phalloplasty (55899)
- Urethroplasty (53430)
- Scrotoplasty (55175, 55180)

Other services (e.g., laboratory, pharmacy, radiology, or behavioral health services) are covered according to the plan design.

For All Other Commercial Products

Gender reassignment surgery is contract exclusion and is non-covered.

For All Commercial Products (including those with coverage for gender reassignment)

The following procedures are considered cosmetic services and are non-covered:

- Abdominoplasty
- Brow ptosis surgery
- Cervicoplasty
- Chemical exfoliations, peels, abrasions (or dermabrasions or planing for acne, scarring, wrinkling, sun damage or other benign conditions)
- Correction of variations in normal anatomy including augmentation mammoplasty, mastopexy, and correction of congenital breast asymmetry
- Dermabrasion
- Ear piercing or repair of a torn earlobe
- Excision of excess skin or subcutaneous tissue (except panniculectomy as listed above)
- Genioplasty
- Gynecomastia surgery, including but not limited to mastectomy and reduction mammoplasty
- Hair transplants
- Hair removal (including electrolysis epilation)
- Inverted nipple surgery
- Laser treatment for acne and acne scars
- Osteoplasty - facial bone reduction
- Otoplasty
- Procedures to correct visual acuity including, but not limited to, cornea surgery or lens implants
- Removal of asymptomatic benign skin lesions
- Repeated cauterizations or electrofulguration methods used to remove growths on the skin
- Rhinoplasty
- Rhytidectomy
- Scar revision, regardless of symptoms
- Sclerotherapy for spider veins
- Subcutaneous injection of filling material
- Suction assisted lipectomy
- Tattooing or tattoo removal (except tattooing of the nipple/areola related to a mastectomy)
- Testicular prosthesis surgery
- Treatment of vitiligo
- Voice modification surgery
- Reversal of genital surgery or reversal of surgery to revise secondary sex characteristics

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable Gender/Sex Reassignment benefits/coverage.

BACKGROUND

Gender identity disorder (GID) is the formal diagnosis used by professionals to describe persons who experience significant gender dysphoria (discontent with their biological sex and/or birth gender).

DSM V uses the term “gender dysphoria” instead of GID because of stigmatization associated with the term gender identity disorder. Additionally, the diagnosis grouping has been moved out of the sexual disorder category and moved into its own.

DSM V criteria:

1. Discomfort with one’s assigned sex or gender role for period of at least six months, as manifested by at least two of the following indicators:
 - a. Feeling of incongruence between one’s felt gender identity and one’s primary and secondary sex characteristics;
 - b. Desire to be rid of one primary and secondary sex characteristics;
 - c. Desire for the sex characteristics of the other sex;
 - d. Desire to be the other sex;
 - e. Desire to be treated as the other sex;
 - f. Belief that one has the feelings and reactions typical of the other sex.
2. The individual does not have an intersex or developmental condition;
3. The condition causes clinically significant distress or impairment in social, occupational, or other areas of functioning;
4. “Gender identity disorder not otherwise specified” is proposed to include individuals who cannot be diagnosed as having a specific gender identity disorder but experience distress and impairment as a result of their gender identity.

In 2010, the World Professional Association for Transgender Health (WPATH) released a statement noting that “the expression of gender characteristics, including identities that are not stereotypically associated with one’s assigned sex at birth is a common and culturally diverse human phenomenon [that] should not be judged as inherently pathological or negative.” Accordingly, transsexual, transgender, and gender nonconforming persons are not intrinsically disordered. Rather, the distress of gender dysphoria, when present, is the matter that may be diagnosable and for which several therapeutic options are available.

Gender reassignment surgery is one treatment option. GRS is not a single procedure, but part of a complex process involving multiple medical, psychiatric, and surgical modalities performed in conjunction with each other to help the candidate for gender reassignment achieve successful behavioral and medical outcomes. Before undertaking GRS, candidates need to undergo important medical and psychological evaluations, and begin medical therapies and behavioral trials to confirm that surgery is the most appropriate treatment choice.

Therapeutic approaches include psychological interventions and gender reassignment therapy, including hormonal interventions that masculinize or feminize the body, and surgical interventions that change the genitalia and other sex characteristics. Gender identity disorders may manifest at childhood, adolescence, or adulthood.

The surgical procedures for male-to-female individuals, also known as “transwomen” may include: orchiectomy, penectomy, vaginoplasty, clitoroplasty, labioplasty breast augmentation, trachea shave/reduction thyroid chondroplasty, and techniques include penile skin inversion, pedicled colosigmoid transplant, and free skin grafts to line the neovagina. For female-to male persons, also known as “transmen”

surgery may include hysterectomy, ovariectomy, vaginectomy, salpingoophorectomy, metoidioplasty, scrotoplasty, urethroplasty, placement of testicular prostheses, and phalloplasty.

Prior to surgery, patients typically undergo hormone replacement therapy for a period of 12 continuous months. Biological females are treated with testosterone to increase muscle and bone mass, decrease breast size, increase clitoris size, increase facial and body hair, arrest menses, and deepen the voice. Biological males are treated with anti-androgens and estrogens to increase percentage of body fat compared to muscle mass, decrease body hair, decrease testicular size, decrease erectile function, and increase breast size.

Individuals diagnosed with gender dysphoria also must undertake real-life experience living in the identity-congruent gender role. This provides sufficient opportunity for patients to experience and socially adjust in their desired role before undergoing irreversible surgery. During this experience, patients should present themselves consistently, on a day-to-day basis and across all life settings, in their desired gender role. Changing gender role can have profound personal and social consequences, and individuals must demonstrate an awareness of the challenges and the ability to function successfully in their gender role.

In 2009 the Endocrine Society published a clinical practice guideline for endocrine treatment of transsexual persons (Hembree, et al., 2009). As part of this guideline, the endocrine society recommends that transsexual persons consider genital sex reassignment surgery only after both the physician responsible for endocrine transition therapy and the mental health professional find surgery advisable; that surgery be recommended only after completion of at least one year of consistent and compliant hormone treatment; and that the physician responsible for endocrine treatment advise the individual for sex reassignment surgery and collaborate with the surgeon regarding hormone use during and after surgery.

Sex reassignment surgical procedures for diagnosed cases of GID should be recommended only after a comprehensive evaluation by a qualified mental health professional. The surgeon should have a demonstrated competency and extensive training in sexual reconstructive surgery. Long-term follow-up is highly recommended.

Comprehensive evaluation is generally supported by the following documentation:

1. Letters that attest to the psychological aspects of the candidate's GID.
 - a. One of the letters must be from a behavioral health professional with a doctoral degree (who is capable of adequately evaluating if the candidate has any co-morbid psychiatric conditions);
 - b. One of the letters must be from the candidate's physician or behavioral health provider, who has treated the candidate for a minimum of 12 months (Note: if the candidate has not been treated continuously by one clinician for 12 months but has transferred care from one clinician to a second clinician, then both clinicians must submit documentation and their combined treatment must have been for 12 months). The letter or letters must document the following:
 - i. Whether the author of the letter is part of a gender identity disorder treatment team; and
 - ii. The candidate's general identifying characteristics; and
 - iii. The initial and evolving gender, sexual, and other psychiatric diagnoses; and
 - iv. The duration of their professional relationship including the type of psychotherapy or evaluation that the candidate underwent; and
 - v. The eligibility criteria that have been met by the candidate; and
 - vi. The physician or mental health professionals rationale for surgery; and
 - vii. The degree to which the candidate has followed the treatment and experiential requirements to date and the likelihood of future compliance; and

- viii. The extent of participation in psychotherapy throughout the 12 month real-life trial,(if such therapy is recommended by a treating medical or behavioral health practitioner); and
 - ix. That during the 12-month, real-life experience (for candidates not meeting the 12-month candidate criteria as noted in 5 and 6, the letter should still comment on the candidates ability to function and experience in the desired gender role), persons other than the treating therapist were aware of the candidate’s experience in the desired gender role and could attest to the candidate’s ability to function in the new role.
 - x. That the candidate has, intends to, or is in the process of acquiring a legal gender identity-appropriate name change; and
 - xi. Demonstrable progress on the part of the candidate in consolidating the new gender identity, including improvements in the ability to handle:
 - 1. Work, family, and interpersonal issues;
 - 2. Behavioral health issues, should they exist. This implies satisfactory control of issues such as:
 - a. Sociopathy
 - b. Substance abuse
 - c. Psychosis
 - d. Suicidality
- c. If the letters specified in 1a and 1b above come from the same clinician, then a letter from a second physician or behavioral health provider familiar with the candidate corroborating the information provided by the first clinician is required;
- a. A letter of documentation must be received from the treating surgeon. If one of the previously described letters is from the treating surgeon then it must contain the documentation noted in the section below. All letters from a treating surgeon must confirm that:
- i. The candidate meets the “candidate criteria” listed in this policy; and
 - ii. The treating surgeon feels that the candidate is likely to benefit from surgery; and
 - iii. The surgeon has personally communicated with the treating mental health provider or physician treating the candidate; and
 - iv. The surgeon has personally communicated with the candidate and that the candidate understands the ramifications or surgery.

CODING

The following codes, when done for the purpose of gender reassignment for those limited groups are covered when the criteria are met:

- 19301
- 19303
- 19304
- 19316
- 19324
- 19325
- 19350
- 31899
- 53430
- 54125
- 54520

54690
55175
55180
56625
56800
56805
56810
57106
57107
57110
57111
57291
57292
57335
58150
58180
58260
58262
58275
58280
58285
58290
58291
58541
58542
58543
58544
58550
58552)
58553
58554

The following CPT codes are not to be used for pricing or claims processing. Claims should be filed with the specific procedures:

55970 55980

RELATED POLICIES

None

PUBLISHED

Provider Update December 2015

Provider Update, August 2015

Provider Update, November 2014

Provider Update, January 2014

REFERENCES

1. Becker S, Bosinski HAG, Clement U, Eicher WM, Goerlich TM, Hartmann U, et al. (1998) German standards for the treatment and diagnostic assessment of transsexuals. IJT 2/4. Available at URL address: <http://www.symposion.com/ijt/ijtc0603.htm>

2. Day P. Trans-gender Reassignment Surgery. Tech Brief Series. New Zealand Health Technology Assessment. NZHTA Report February 2002, Volume 1, Number 1. Available at URL address: <http://nzhta.chmeds.ac.nz/index.htm#tech>

3. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition. Text Revision (DSM-IV -TR). American Psychiatric Association. American Psychiatric Association, Incorporated. July 2000.
4. ECRI Institute. Hotline Response [database online]. Plymouth Meeting (PA): ECRI Institute; 2007 October. Sexual reassignment for gender identity disorders. Available at URL address: <http://www.ecri.org>
5. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, Tangpricha V, Montori VM; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2009 Sep;94(9):3132-54.
6. Landen M, Walinder J, Hambert G, Lundstrom B. Factors predictive of regret in sex reassignment. *Acta Psychiatr Scand*. 1998 Apr;97(4):284-9.
7. Lawrence AA. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. *Arch Sex Behav*. 2003 Aug;32(4):299-315.
8. Maharaj NR, Dhari A, Wiersma R, Moodley J. Intersex conditions in children and adolescents: surgical, ethical, and legal considerations. *J Pediatr Adolesc Gynecol*. 2005 Dec;18(6):399-402.
9. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. *J Clin Endocrinol Metab*. 2003 Aug;88(8):3467-73.
10. Smith YL, van Goozen SH, Cohen-Kettenis PT. Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. *J Am Acad Child Adolesc Psychiatry*. 2001 Apr;40(4):472-81.
11. Sutcliffe PA, Dixon S, Akehurst RL, Wilkinson A, Shippam A, White S, Richards R, Caddy CM. Evaluation of surgical procedures for sex reassignment: a systematic review. *J Plast Reconstr Aesthet Surg*. 2009 Mar;62(3):294-306; discussion 306-8.
12. World Professional Association for Transgender Health. The Harry Benjamin International Gender Dysphoria Association. Standards of Care for Gender Identity Disorders. 6th version. 2001 Feb. Available at URL address: http://www.wpath.org/publications_standards.cfm
13. Zucker KJ. Intersexuality and gender identity disorder. *J Pediatr Adolesc Gynecol*. 2002 Feb;15(1):3-13

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

